Literature DB >> 22728

The disposition of timolol in man.

P Vermeij, M el-Sherbini-Schepers, P A van Zwieten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 22728     DOI： 10.1111/j.2042-7158.1978.tb13155.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN： 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  8 in total

Review 1.  Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.

Authors:  D Ormrod; K McClellan
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

2.  Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists?

Authors:  D B Jack
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

3.  Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.

Authors:  P C O'Connor; J M Arnold; A N Brown; R J Francis; M B Finch; D B Galloway; D W Harron; D G McDevitt; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

4.  Plasma timolol levels after oral and intravenous administration.

Authors:  O F Else; H Sorenson; I R Edwards
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  Pharmacokinetics of oral timolol studied by mass fragmentography.

Authors:  J B Fourtillan; P Courtois; M A Lefebvre; J Girault
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

Review 6.  Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

7.  Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

Authors:  P H Hinderling; O Schmidlin; J K Seydel
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

8.  Pharmacokinetics of intravenous timolol in patients with acute myocardial infarction and in healthy volunteers.

Authors:  J A Vedin; J K Kristianson; C E Wilhelmsson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.